|
|
Article: Beta blocker meets stricter criterion: nebivolol can lower DBP by 15 mm Hg or more.
- Article from:
- Renal & Urology News
- Article date:
- August 1, 2008
- Author:
CopyrightCOPYRIGHT 2008 Haymarket Media, Inc. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
NEW ORLEANS -- Two pooled analyses of the newest beta blocker, nebivolol, demonstrate that it is effective as once daily monotherapy in stage 1 and 2 hypertension using more stringent criteria than normal to measure BP control.
It also carries few of the side effects associated with typical beta blockers, researchers reported here at 23rd annual scientific meeting of the American Society of Hypertension.
Approved by the FDA in January and marketed as Bystolic, nebivolol is a vasodilator that maintains cardiac output and increases stroke volume while decreasing peripheral vascular resistance. Its enhancement of endothelial nitric oxide is believed to be ...